World Vaccine Congress 2010

Article

The World Vaccine Congress Lyon is the premiere vaccine conference addressing all major vaccine markets.

The 12th annual World Vaccine Congress Lyon, organized by Terrapinn Ltd., opened on October 4, 2010, to provide solutions to today's biggest global challenges. Speakers, delegates, and exhibitors came from mainly European and North American regions to share their expertise, experience and services. The World Vaccine Congress Lyon is the premiere vaccine conference addressing all major vaccine markets, including influenza, HPV, pneumococcal, and meningococcal.

Sponsors and exhibitors present at the Congress include: Encorium, Millipore, Merck, GE Healthcare, Charles River labs, Eurocine, PAA Labs, SAFC, Fisher Clinical Services, Novozymes, Eurogentec, Vactia, Lonza, Luminex, ITS Innovation, AVIR Green Hills Biotech, Lipotek, Abd Serotec, Werum Software, Vibalogics, BioKinetic Europe and Accelovance.

Key themes for this year’s event include:

  • From R&D to S&E; a paradigm shift for vaccine R&D
  • Innovative vaccine differentiation and indication expansion
  • New vaccine franchise evolution
  • Penetrating emerging markets for revenue growth
  • Creative market-access strategies, market innovation and expansion
  • Capturing value and contributing to partnership success
  • Novel vaccine engineering, adjuvant development and antigen delivery advances
  • Accessing innovation: the increasing importance of externalisation
  • Advancing regulatory pathways and bridging the safety divide

To learn more about the 12th annual World Vaccine Congress Lyon and to download the conference brochure, click here.

A list of speakers who are scheduled to present at this year’s Congress is available here.

Related Videos
Addressing HS Risks at the Genetic Level, with Kai Li, BSc
Building a Psoriasis Knockout Regimen Around Risankizumab, with Andrew Blauvelt, MD, MBA
Joel Gelfand, MD, MSCE: Phototherapy Utility in Psoriasis
Pediatric Hidradenitis Suppurativa Severity not Linked to Obesity
Rizankizumab and the KNOCKOUT Study, with Andrew Blauvelt, MD, MBA
© 2024 MJH Life Sciences

All rights reserved.